Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel PI3K Inhibitor 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4- morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941)